2023 was a big year for CRISPR-based gene editing but challenges remain
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetical
Comment here to discuss with all recipients or tap a user's profile image to discuss privately.